What is the cost of Stem Cell Therapy for Parkinson’s Disease?
At Stem Cell Mexico, stem cell therapy for Parkinson's disease typically costs between $7,000 and $9,500 USD.

The final price depends on the stage of the disease, your main symptoms, the number of cells recommended, the route of administration, whether more than one session is planned, the level of support you need during your stay (for example, help with mobility or a caregiver nearby) and how long you require medical observation. Your complete cost is confirmed in writing after a medical evaluation and before any deposit, and only the items expressly listed in your quote are included.
Parkinson's disease is one of the most active areas of stem cell research in the world, and also one where the details matter a great deal. Different cell types, routes and goals produce very different results. This guide explains what you are paying for, what science currently supports and how to evaluate whether a regenerative approach fits your situation.
Why Parkinson's treatment plans cost more than local injections
Neurological protocols usually require:
- Larger cell doses, because cells are delivered systemically rather than into one small area.
- A more detailed evaluation, including neurological history, medication schedule, imaging when available and cardiovascular screening.
- Closer observation, often with an overnight stay and nursing support, especially for patients with balance problems, low blood pressure on standing or advanced disease.
- Practical accommodations, such as timing the procedure around your levodopa doses, mobility assistance and accessible transportation.
These elements explain why Parkinson's plans fall in a higher range than orthopedic treatments.
What the price usually includes
Each plan is personalized, but a typical quote includes:
- Consultation with the doctor and stem cell specialist, reviewing your diagnosis, symptom history, medications and any prior treatments such as deep brain stimulation.
- Pre-treatment laboratory testing: complete blood count, comprehensive metabolic panel, urinalysis and tumor markers.
- Allogeneic mesenchymal stromal cells (MSCs) derived from donated umbilical cord tissue (Wharton's jelly), prepared for your scheduled date.
- Administration according to your plan, most commonly intravenous (IV) infusion, under medical supervision.
- Medical observation with nursing care, ground transportation between the San Diego airport area and the clinic, a dedicated patient coordinator and structured follow-up.
Flights, hotel nights outside the clinic and companion lodging are usually separate unless listed in your quote.
Why the price varies within the range
Stage and main symptoms
Someone in the early years after diagnosis with mild tremor has different goals from someone living with advanced disease, frequent "off" periods, falls or cognitive changes. Your doctor uses your symptom profile to define realistic goals and a protocol.
Cell dose and number of sessions
Higher doses or a plan that anticipates repeated sessions increase the total. More is not automatically better; the dose is selected based on body weight, health status and treatment goals.
Level of care during your stay
Patients who need help with transfers, medication administration on a strict schedule or extra nights of observation require more resources.
What Parkinson's disease is and how it is treated today
Parkinson's disease is a progressive neurological condition in which nerve cells that produce dopamine, in a brain region called the substantia nigra, gradually stop working and die. Dopamine is essential for smooth, coordinated movement. When levels fall, symptoms appear: tremor, slowness of movement (bradykinesia), stiffness and balance problems. Many people also experience non-motor symptoms such as constipation, sleep disorders, loss of smell, depression, anxiety and, over time, cognitive changes.
According to the U.S. National Institute of Neurological Disorders and Stroke (NINDS), there is currently no cure, but symptoms can be managed effectively for many years. Standard care includes:
- Medications such as levodopa, dopamine agonists and MAO-B inhibitors, adjusted over time.
- Deep brain stimulation (DBS) for selected patients with motor fluctuations.
- Exercise, physical therapy, speech therapy and occupational therapy, which have strong evidence for maintaining function.
Any regenerative therapy should be considered in addition to this care, with your neurologist informed. Parkinson's medications should never be stopped or changed without medical guidance.
Two very different stem cell strategies
It is essential to separate two approaches that are often confused online.
1. Dopamine cell replacement
Scientists grow dopamine-producing nerve cells from pluripotent stem cells (embryonic or induced pluripotent stem cells) and transplant them surgically into the brain, specifically into the putamen, where dopamine is needed. The goal is to replace the lost cells. This is neurosurgery performed within regulated clinical trials.
2. Supportive or immunomodulatory therapy
Mesenchymal stromal cells are not expected to become dopamine neurons. They are studied because they release anti-inflammatory and neurotrophic signals that may reduce neuroinflammation, protect vulnerable neurons and support the brain environment. These cells are usually given by IV infusion. This is the rationale behind umbilical cord MSC protocols.
Results from one strategy cannot be applied to the other.
What the evidence says
Cell replacement is advancing quickly: In 2025, Nature published a phase 1 trial (Tabar and colleagues) in which 12 people with Parkinson's received surgically implanted dopamine neuron progenitors derived from human embryonic stem cells. The trial met its safety goals at 12 months, with no adverse events attributed to the cells and no graft-induced dyskinesias through 18 months. Imaging showed graft survival, and the higher-dose group had substantial improvements in motor scores measured in the "off" medication state. A similar Japanese trial using induced pluripotent stem cell-derived cells was published at the same time. These studies represent a major scientific milestone, and further trials are under way.
Mesenchymal stromal cells: A phase 1 trial published in Movement Disorders (Schiess and colleagues, 2021) tested single IV infusions of allogeneic bone-marrow-derived MSCs at increasing doses in people with mild to moderate Parkinson's. The infusions were safe and well tolerated, and exploratory measures suggested possible benefits and reduced inflammatory markers at the highest dose. The same group later conducted a randomized trial to explore efficacy further. Overall, MSC evidence in Parkinson's shows a favorable safety profile and biologically plausible effects.
What this means for you: The field is genuinely promising. Cell replacement may eventually change how Parkinson's is treated, but it is currently available only in clinical trials. Supportive MSC therapy may help with energy, stiffness or quality of life in some patients; responses vary, and it is not designed to stop disease progression.
Regulatory context
No stem cell therapy is currently approved by the FDA or the European Medicines Agency for Parkinson's disease. In Mexico, cell therapies are regulated by COFEPRIS and must come from licensed laboratories.
Who may be a candidate
Evaluation typically considers:
- A confirmed diagnosis of Parkinson's disease by a neurologist (as opposed to atypical parkinsonism, which behaves differently).
- Stage, main symptoms and current medication response.
- General health, blood pressure stability and fall risk.
- No active infection and no cancer history within the past five years.
- Willingness to continue neurological care, exercise and therapy after treatment.
What results patients commonly ask about
Will I be able to reduce my medication? This should not be expected. Any medication adjustment must be made by your neurologist based on observed changes.
When might I notice something? If changes occur, they are typically evaluated over two to six months.
How will we know if it helped? By comparing standardized measures such as the MDS-UPDRS, timed walking tests, symptom diaries and your neurologist's observations before and after treatment.
What can affect outcomes
- Stage and duration of the disease.
- Regular exercise, which is one of the most consistently beneficial interventions in Parkinson's.
- Sleep, nutrition, constipation management and mood.
- Medication timing and adherence.
Preparing for treatment
Bring a complete medication list with exact timing, since levodopa schedules should be maintained during travel and treatment. Share neurology reports and any imaging. Tell us about orthostatic hypotension, swallowing problems, hallucinations or falls so the team can plan safety measures. Recording a short baseline video of walking and tremor helps compare changes later.
Risks and limitations
IV infusions of MSCs have generally been well tolerated in clinical studies, with possible temporary fever, headache or fatigue, and rare risks such as allergic reactions or thrombotic events. Surgical cell replacement carries neurosurgical risks and is performed only in trials. Results vary between patients.
Questions to ask during your evaluation
- Is this a supportive therapy or cell replacement, and how is it delivered?
- What dose do you recommend, and why?
- How will we measure change?
- How will you coordinate with my neurologist?
- What exactly is included in my quote?
Bottom line
Stem cell therapy for Parkinson's disease at Stem Cell Mexico typically ranges from $7,000 to $9,500 USD, reflecting larger doses, careful screening and supportive care. Cell replacement research is advancing in clinical trials, while supportive MSC therapy shows a good safety profile. A medical evaluation can help determine whether this type of regenerative treatment is appropriate for your symptoms, goals and medical history, and gives you a written quote before you decide.
References
- National Institute of Neurological Disorders and Stroke (NINDS, NIH): Parkinson's disease (opens in a new tab)
- Tabar V et al. Phase I trial of hES cell-derived dopaminergic neurons for Parkinson's disease. Nature, 2025 (opens in a new tab)
- Schiess M et al. Allogeneic bone marrow-derived mesenchymal stem cell safety in idiopathic Parkinson's disease. Movement Disorders, 2021 (opens in a new tab)
